Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdensome impact on quality of life. 15 June 2021
Pharmaceutical
The Russian government has changed the requirements for the extension of patents for drugs in the domestic market, according to recent statements, made by some senior state officials and local media, reports The Pharma Letter’s local correspondent. 15 June 2021
Biosimilars
Shares of pharmaceutical companies continued their upward journey at the bourses in India, with the pharma index hitting a new high. Pharma stocks are in focus amid the ongoing COVID-19 pandemic, helping register a strong gain for companies like Aurobindo Pharma, Dr Reddy’s Laboratories and Cadila Healthcare, reports The Pharma Letter’s India correspondent. 15 June 2021
Pharmaceutical
Although drug sales in Russia fell 13% in the first four months of the current year in volume terms to 1.7 billion packages, they grew by 4.8% to 390 billion roubles ($5.4 billion) in terms of value, reports The Pharma Letter’s local correspondent. 15 June 2021
Biotechnology
The adjectives that accompanied the US approval of the first drug to treat Alzheimer’s disease in nearly two decades sought to sum up the apparent magnitude of the moment. 8 June 2021
Pharmaceutical
Leading Russian pharmaceutical producers and foreign companies operating in the local market have called on the national government to increase the volume of support for companies that are involved in the development and launch of innovative drugs in the domestic market, The Pharma Letter’s local correspondent reports. 8 June 2021
Pharmaceutical
An Expert View from Mark Doyle, co-founder of UK company The Method and creator of A Life in a Day experience, which seeks to support the pharmaceutical and healthcare industries in developing patient-centric strategies for more impactful engagement. 7 June 2021
Pharmaceutical
The Russian Parliament (State Duma) has finally approved legislation that allows the production of original drugs intended for exports without the permission of a patent holder, according to recent statements by the press-service of the Duma and some local media, reports The Pharma Letter’s local correspondent 1 June 2021
Generics
A sharp rise in the price of raw material of key drugs used in the treatment of COVID-19, as well as other active pharmaceutical ingredients (API) over the last few weeks, has unnerved Indian drug manufacturers. 1 June 2021
Pharmaceutical
The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on June 4, with more than 2,500 abstract presentations representing cutting-edge research from around the world. 28 May 2021
Pharmaceutical
A new Russian vaccine against COVID-19 and influenza is being developed at Natsimbio, a subsidiary of the Russian state corporation Rostec, according to recent statements by sources close to the company and local analysts. 25 May 2021
Pharmaceutical
The Russian government will use the mechanism of interventions in the domestic pharmaceutical market to tighten control of drug prices, according to recent statements by some senior state officials and local media, reports The Pharma Letter’s local correspondent. 25 May 2021
Pharmaceutical
The US Food and Drug Administration strictly prohibits the distribution of counterfeit, diverted, subpotent, substandard, adulterated, misbranded, and expired drugs that pose a serious threat to life. Nevertheless, such drugs continue to end up in circulation, compromising patient safety. 24 May 2021
Pharmaceutical
In support of Ehlers-Danlos Syndrome (EDS) Awareness Month, we explore the pharmacological landscape of this rare condition. 24 May 2021
Pharmaceutical
AJ Ploszay, vice president of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by the digital buying trends driven by COVID-19, are influencing a similar shift in the commercial pharma space. 20 May 2021
Biotechnology
At this year’s ASCO meeting, Bristol Myers Squibb will present the first data from a Phase III trial evaluating a LAG-3-blocking antibody. 20 May 2021
Pharmaceutical
US pharma giant Merck & Co’s Russian MSD unit has revoked the registration certificate on its Belsomra (suvorexant) next-generation sleeping pill in Russia, due to the inability of the company to generate sales in the local market, reports The Pharma Letter’s local correspondent. 18 May 2021
Biotechnology
The Russian drugmaker R-Pharm will start the production of UK-based AstraZeneca’s COVID-19 vaccine at its facilities in Russia starting in June of the current year, according to recent statements by R-Pharm’s chief executive Vasily Ignatiev, as well as local media, reports the Pharma Letters local correspondent. 18 May 2021
Pharmaceutical
The mere notion of the US government supporting any policies that might encourage pharmaceutical patents to be ignored would have seemed inconceivable only 18 months ago. 17 May 2021
Pharmaceutical
An Expert View from Manjit Singh, chairman of the Pharmaceutical Supply Chain Initiative, which tries to foster responsible supply chains, highlighting the issue of antibiotic resistance and the often-underestimated threat coming from the discharge of material in environment. 14 May 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze